Quarterly report (Form 10-Q)
Caris Life Sciences 10-Q for Quarter ended Mar 31, 2026
Filing excerpt
Revenue from clinical cases for patients covered by Medicare represented approximately 41.2% and 54.3% of our molecular profiling services revenue for the three months ended March 31, 2026 and 2025, respectively.